SCHEMBL23714788

SCHEMBL23714788

CC(C)(C)OC(=O)NCc1cccc(-c2cccc(-c3csc(N)n3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 3/20 0.50
HRH4 Q9H3N8 2/20 0.50
HDAC3 O15379 4/20 0.45
HDAC1 Q13547 4/20 0.45
HDAC2 Q92769 3/20 0.45
HDAC10 Q969S8 3/20 0.45
PRMT6 Q96LA8 1/20 0.45
ACACB O00763 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ACACA Q13085 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
HDAC8 Q9BY41 2/20 0.44
BRD4 O60885 1/20 0.44
CREBBP Q92793 1/20 0.44
GLS O94925 3/20 0.44
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714789 0.85 HDAC3 (0.54) HDAC3HDAC1HDAC2HDAC10CYP3A4
SCHEMBL2582485 0.84 LTA4H (0.48) HDAC1HDAC6ROCK2ROCK1MAPT
SCHEMBL8648939 0.82 HRH2 (0.57) HRH2HRH4PRMT6ROCK2ROCK1
SCHEMBL30504293 0.81 HDAC1 (0.56) HDAC1BRD4CREBBPGLS
SCHEMBL21812584 0.81 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC10PRMT6
SCHEMBL16410438 0.81 BRD4 (0.51) HDAC1ACACBCYP1A2CYP3A4CYP2C9
SCHEMBL301717 0.79 PRMT6 (0.56) HDAC1PRMT6CYP3A4CYP2C9BRD4
SCHEMBL18664426 0.79 HDAC1 (0.60) HDAC1BRD4CREBBPGLS
SCHEMBL7121746 0.79 HDAC3 (0.63) HRH4HDAC3HDAC1HDAC2HDAC10
SCHEMBL16410240 0.78 BRD4 (0.53) HDAC1BRD4CREBBPGLSGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HRH2 3671/4885HRH4 3580/4885HDAC3 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.